Table 3.
Summary of the assumed intervention effect sizes and power
| Endpoint | Patient Cohort Characteristics (defining cohort eligible for intervention) | Baselinea Percentage | Post-intervention Percentage | Power |
|---|---|---|---|---|
| A: Aspirin (aspirin or other antithrombotic prescribed) | Aged 18 years and older with ischemic vascular disease without a contraindication to aspirin | 60% | 70% | > 95% |
| B1: Blood Pressure Management 1 (blood pressure adequately controlled) | Aged 18–85 who had a diagnosis of hypertension | 65% | 70% | > 95% |
| B2: Blood Pressure Management 2 (blood pressure adequately controlled as per co-morbidity-adjusted targets) | Aged 18–85 who had a diagnosis of hypertension | 65% | 70% | > 95% |
| C1: Cholesterol Management 1:** (fasting LDL test AND ≤ LDL goal) |
Aged 20–79 | 15% | 25% | > 95% |
| C2: Cholesterol Management 2:** (fasting LDL test AND prescribed statin if indicated) |
Aged 20–79 | 15% | 25% | > 95% |
| S: Smoking cessation support (screening about tobacco AND received cessation counseling if tobacco user) | Aged 18 years and older | 60% | 70% | > 95% |
aEstimates for the baseline percentages for aspirin use, blood pressure management, and smoking cessation support are based on Oklahoma Foundation for Medical Quality (OFMQ) primary care practice initiatives in the state of Oklahoma
**The C1 and C2 measures were calculated as the product of the probability of having a fasting LDL test (estimated to be 0.3) multiplied by the probability of having an LDL measure below the target (estimated to be 0.50) or being prescribed a statin if indicated (estimated to be 0.5) conditional on having a fasting LDL test
Abbreviation: LDL low-density lipoprotein